UNSPSC 51131663: Dabigatran etexilate

This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2E18WX195X. European Medicines Agency schedules Dabigatran etexilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20521. Dabigatran etexilate generally arises in the molecular formula C34H41N7O5.

UNSPSC 51131663 Dabigatran etexilate is a Commodity code representing a specific anticoagulant pharmaceutical product, yet the recent state and local procurement activity tagged under this code does not reflect pharmaceutical procurement. The single recent opportunity on record—Sourcewell RFP #061626, posted May 12, 2026 with a response deadline of June 16, 2026—solicits law enforcement equipment on behalf of a cooperative purchasing vehicle serving multiple jurisdictions, counties, and public entities. This mismatch between the code's pharmaceutical scope and the actual solicitation suggests either a tagging error in the source data or that dabigatran etexilate procurement through state and local channels is not currently active in the tracked opportunity set. No other recent state and local solicitations for dabigatran etexilate or related anticoagulant pharmaceuticals appear in the available records.

Sourcewell, a Minnesota local government cooperative purchasing entity, is the issuing body for the single tracked opportunity. The RFP framework is designed to serve participating jurisdictions across multiple states (including Washington counties: Franklin, Grant, Grays Harbor, Chelan, and Yakima) and extends to higher education, K-12 school districts, nonprofit organizations, tribal governments, and other public entities throughout the United States and Canada. Vendors must submit proposals through the Sourcewell Procurement Portal by June 16, 2026 at 3:30 p.m. Central Time. The code shows no meaningful recent activity aligned with pharmaceutical procurement at the state and local level; business development professionals evaluating dabigatran etexilate procurement opportunities should confirm whether this code represents their actual target market or whether pharmaceutical purchasing in state and local procurement operates under different UNSPSC classifications.